image
Healthcare - Biotechnology - NASDAQ - US
$ 6.23
-8.89 %
$ 428 M
Market Cap
-2.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EYPT stock under the worst case scenario is HIDDEN Compared to the current market price of 6.23 USD, EyePoint Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EYPT stock under the base case scenario is HIDDEN Compared to the current market price of 6.23 USD, EyePoint Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EYPT stock under the best case scenario is HIDDEN Compared to the current market price of 6.23 USD, EyePoint Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
43.3 M REVENUE
-5.97%
-146 M OPERATING INCOME
-94.30%
-131 M NET INCOME
-84.86%
-126 M OPERATING CASH FLOW
-6732.05%
-219 M INVESTING CASH FLOW
-6517.04%
164 M FINANCING CASH FLOW
-12.32%
11.6 M REVENUE
10.11%
-45.2 M OPERATING INCOME
-38.14%
-41.4 M NET INCOME
-41.00%
-35.8 M OPERATING CASH FLOW
8.15%
-96 M INVESTING CASH FLOW
-592.50%
152 M FINANCING CASH FLOW
1175.41%
Balance Sheet EyePoint Pharmaceuticals, Inc.
image
Current Assets 383 M
Cash & Short-Term Investments 371 M
Receivables 607 K
Other Current Assets 11.8 M
Non-Current Assets 35.2 M
Long-Term Investments 0
PP&E 29.2 M
Other Non-Current Assets 5.98 M
88.64 %2.82 %6.97 %
Current Liabilities 49 M
Accounts Payable 11.7 M
Short-Term Debt 0
Other Current Liabilities 37.3 M
Non-Current Liabilities 32.9 M
Long-Term Debt 0
Other Non-Current Liabilities 32.9 M
14.30 %45.54 %40.16 %
EFFICIENCY
Earnings Waterfall EyePoint Pharmaceuticals, Inc.
image
Revenue 43.3 M
Cost Of Revenue 3.71 M
Gross Profit 39.6 M
Operating Expenses 185 M
Operating Income -146 M
Other Expenses -15 M
Net Income -131 M
RATIOS
91.42% GROSS MARGIN
91.42%
-337.06% OPERATING MARGIN
-337.06%
-302.43% NET MARGIN
-302.43%
-38.89% ROE
-38.89%
-31.27% ROA
-31.27%
-39.51% ROIC
-39.51%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis EyePoint Pharmaceuticals, Inc.
image
Net Income -131 M
Depreciation & Amortization 1.54 M
Capital Expenditures -4.05 M
Stock-Based Compensation 36.7 M
Change in Working Capital -27.8 M
Others -40.8 M
Free Cash Flow -130 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets EyePoint Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for EYPT of $25.8 , with forecasts ranging from a low of $22 to a high of $30 .
EYPT Lowest Price Target Wall Street Target
22 USD 253.13%
EYPT Average Price Target Wall Street Target
25.8 USD 314.13%
EYPT Highest Price Target Wall Street Target
30 USD 381.54%
Price
Max Price Target
Min Price Target
Average Price Target
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership EyePoint Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
384 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
185 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. zacks.com - 1 week ago
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2025, and highlighted recent corporate developments. globenewswire.com - 1 week ago
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments. globenewswire.com - 2 weeks ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). globenewswire.com - 1 month ago
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference on Friday, April 4, 2025 at 10:00 a.m. ET. globenewswire.com - 1 month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). globenewswire.com - 2 months ago
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Yigal Nochomovitz - Citigroup Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Debanjana Chatterjee - JonesTrading Gregory Harrison - Scotiabank Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning. seekingalpha.com - 2 months ago
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.33 per share a year ago. zacks.com - 2 months ago
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments – Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2024, and highlighted recent corporate developments. globenewswire.com - 2 months ago
EyePoint Announces Participation at Upcoming Investor Conferences WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: Leerink Partners Global Healthcare Conference Forum: Corporate PresentationDate: Tuesday, March 11, 2025Time: 4:20 p.m. globenewswire.com - 2 months ago
8. Profile Summary

EyePoint Pharmaceuticals, Inc. EYPT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 428 M
Dividend Yield 0.00%
Description EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Contact 480 Pleasant Street, Watertown, MA, 02472 https://eyepointpharma.com
IPO Date Jan. 27, 2005
Employees 165
Officers Ms. Jennifer Leonard Chief People Officer & Senior Vice President of IT Ms. Isabelle Lefebvre Chief Regulatory Officer Dr. Marcia Sellos-Moura Ph.D. Senior Vice President and Head of Development & Program Management Dr. Jay S. Duker M.D. President, Chief Executive Officer & Director Dr. Ramiro Ribeiro M.D., Ph.D. Chief Medical Officer Mr. Michael J. Maciocio Chief Manufacturing Officer Mr. Ron I. Honig Esq. Chief Legal Officer & Company Secretary Mr. David Scott Jones M.A. Senior Vice President & Chief Commercial Officer Dr. Anna Kluczewska Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd